Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Aquestive Therapeutics ( (AQST) ) has issued an announcement.
On August 11, 2026, Aquestive Therapeutics reported second quarter 2026 results and detailed progress on its Anaphylm sublingual epinephrine film program following a January 30, 2026 FDA Complete Response Letter. The company completed required human factors and pharmacokinetic studies, plans to resubmit the Anaphylm NDA in the third quarter of 2026, and is advancing an allergist-focused U.S. launch strategy alongside ex-U.S. regulatory filings targeted for late 2026 and early 2027.
Aquestive highlighted expansion of its AdrenaVerse platform through early-stage development of AQST-108 topical epinephrine for dermatologic inflammatory indications, while maintaining emphasis on Anaphylm. Commercial manufacturing collaborations remained steady, with total revenue rising 38% year over year to $13.8 million in the second quarter of 2026, driven by higher Suboxone supply and royalty income, and the company reiterated its expectation for full U.S. approval of Libervant after orphan drug exclusivity expires in January 2027.
Aquestive also noted that Cosette Pharmaceuticals’ April 8, 2026 acquisition of Sympazan rights preserves Aquestive’s manufacturing and royalty stream under existing licensing terms. The combination of pipeline momentum, particularly in epinephrine rescue and dermatology, and growing manufacturing volumes positions the company to leverage its oral and film delivery technology across multiple indications, while offering stakeholders a diversified mix of product launches and collaboration-based revenues.
The most recent analyst rating on (AQST) stock is a Buy
with a $6.00 price target.
To see the full list of analyst forecasts on Aquestive Therapeutics stock,
see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
The score is held down primarily by weak financial performance (heavy losses, negative equity, and persistent cash burn). Earnings-call updates provide an offset with clearer regulatory path and improved liquidity, but technicals remain soft and valuation is constrained by ongoing losses.
To see Spark’s full report on AQST stock,
click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a U.S.-based pharmaceutical company that develops and manufactures orally delivered and film-based medicines using proprietary delivery technologies. Its portfolio and collaborations span rescue therapies, epilepsy treatments such as Sympazan and Libervant, and global supply agreements for oral film products including Suboxone, Ondif and Emylif, with a growing focus on allergy and dermatology markets.
The company operates both as a developer of its own pipeline products, notably the Anaphylm sublingual epinephrine film and the AdrenaVerse epinephrine prodrug platform, and as a contract manufacturer for partners, generating manufacture, supply, license and royalty revenue. With intellectual property and manufacturing based in the U.S., Aquestive’s supply chain has remained largely unaffected by current and proposed tariffs, supporting reliable global distribution for its partners and products.
Average Trading Volume: 2,112,259
Technical Sentiment Signal: Buy
Current Market Cap: $494.3M
Learn more about AQST stock on TipRanks’ Stock Analysis page.